Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma

Wang, David M.; Fernandez, Anthony P.; Calabrese, Cassandra; Calabrese, L

doi:10.1111/ced.13630

Cited by 13 publications

(7 citation statements)

References 6 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This did not occur with subsequent injections. 22 No reports of HIV-positive psoriasis patients experiencing serious adverse events on adalimumab have been reported.…”

Section: Methodsmentioning

confidence: 99%

Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review

Myers

Thibodeaux

Reddy

et al. 2020

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

Background: The management of psoriatic disease in HIV-positive patients is challenging. Psoriasis in HIV-positive patients is often severe, progressive, and resistant to first- and second-line therapies, including topical treatments, phototherapy, highly active antiretroviral therapy (HAART), and oral retinoids. Other systemic agents used to treat psoriasis, such as methotrexate and cyclosporine, are immunosuppressants and thus many dermatologists may not feel comfortable prescribing them to HIV-positive patients who are already immunocompromised. Biologic agents, which target specific aspects of overactive immune pathways in psoriasis, have revolutionized the management of moderate-to-severe psoriasis. However, data are limited regarding their safety and efficacy in HIV-positive patients. Objective: Report 4 cases of HIV-positive patients managed on biologic therapy and summarize the cases of psoriasis in HIV-positive patients managed on biologic therapy that have been published in dermatologic literature to date. Methods: We searched PubMed and Embase databases using the terms HIV and psoriasis or HIV and psoriatic arthritis combined with one of the 11 biologics currently approved for treating psoriasis. Results: We identified 48 cases of anti-psoriasis biologic therapy (including adalimumab, infliximab, etanercept, ustekinumab, and guselkumab) in HIV-positive patients and added 4. While data are limited, the evidence available suggests biologic agents are safe and efficacious in moderate-to-severe psoriasis and may even have a favorable effect on CD4 and HIV viral counts when used with concomitant HAART. Conclusion: Further research would be helpful to establish practical guidelines for the use of anti-psoriasis biologic therapy in the HIV population, including that of newer agents.

show abstract

“…This did not occur with subsequent injections. 22 No reports of HIV-positive psoriasis patients experiencing serious adverse events on adalimumab have been reported.…”

Section: Methodsmentioning

confidence: 99%

Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review

Myers

Thibodeaux

Reddy

et al. 2020

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

show abstract

“…У части пациентов был немного снижен уровень CD4+ Т-клеток, который в дальнейшем восстановился без изменения АРВТ, отмены ГИБП не потребовалось [31]. Имеется опыт использования ГИБП при сочетании СК и ВИЧ-ассоциированного псориаза, которые развились у пациента, несмотря на проведение АРВТ [32].…”

Section: терапия иврз при вичunclassified

Current issues in the management of patients with HIV infection and rheumatic diseases

Гриднева¹,

Белов²

2021

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

According to experts, the human immunodeficiency virus (HIV) epidemic has a steady downward trend, but the attention of the medical community to this problem is not waning. Before the introduction of highly active antiretroviral therapy, the prevalence of rheumatic manifestations in HIV-infected patients ranged from 3 to 71% and was associated with late stages of infection and severe immunosuppression. HIV-associated arthritis, reactive arthritis, psoriatic arthritis, arthralgias and diffuse infiltrative lymphocytosis syndrome are the most common rheumatic pathologies in HIV. Most people with HIV and musculoskeletal inflammatory disease respond well to NSAIDs, opioids, and basic anti-inflammatory drugs. In cases that are torpid to the abovementioned treatment, the use of biologic disease-modifying antirheumatic drugs may be required.The lecture summarizes modern data on the features of the course and treatment of immunoinflammatory rheumatic diseases in HIV infection.

show abstract

“…In conclusion, although measurement of plasma human herpesvirus 8 viral load before ustekinumab initiation and at the end of the observation period and a more prolonged follow‐up would have been desirable, in the case presented by Wang et al . the KS‐inducing effects of IL‐12 inhibition might have been balanced by the anti‐tumour properties of IL‐23 blockade.…”

mentioning

confidence: 97%

“…We read with great interest the recent article by Wang et al . reporting on a patient with coexistence of psoriasis and HIV‐related Kaposi sarcoma (KS).…”

mentioning

confidence: 99%

Comment on: ‘Treatment of psoriasis with ustekinumab in a patient withHIV‐related Kaposi sarcoma’

et al. 2019

View full text Add to dashboard Cite

Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma

Abstract: Click https://www.wileyhealthlearning.com/ced.aspx for the corresponding questions to this CME article.

Cited by 13 publications

References 6 publications

Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review

Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review

Current issues in the management of patients with HIV infection and rheumatic diseases

Comment on: ‘Treatment of psoriasis with ustekinumab in a patient withHIV‐related Kaposi sarcoma’

Contact Info

Product

Resources

About